Verismo Therapeutics will bring its KIR-CAR T cell platform to the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in 2026. The company plans to show new preclinical data on its mesothelin-targeted multi-chain KIR-CAR T cells. The poster session is set for November 6 at the Phoenix Convention Center. This session will compare the in vivo performance of Verismo's next-generation approach with older single-chain CAR T designs. The SITC 2026 Annual Meeting runs from November 4 to 8 in Phoenix, Arizona. Verismo's poster session is confirmed for this venue and date, according to official event details.
Principal Scientist Nora Yucel, Ph.D., will lead the poster. It will cover the in vivo profile of the KIR-CAR platform. This is the same technology behind SynKIR™-110, now in the STAR-101 Phase 1 Clinical Trial (NCT05568680). The abstract says the multi-chain KIR-based CAR T cells show less exhaustion and lower cytokine release than CD28 or 41BB single-chain CAR T constructs. The safety profile also looks better in these preclinical tests. These results are from animal studies only. No human safety or efficacy data are included. Verismo Therapeutics is a U.S. subsidiary of HLB Innovation. The company is developing SynKIR-110 for solid tumors and SynKIR-310 for blood cancers. This is detailed in a Daum summary of HLB Innovation coverage.
Preliminary Phase 1 results for SynKIR-110, presented at AACR, showed tumor shrinkage and partial responses in some patients, highlighting early clinical activity for Verismo's KIR-CAR platform.
How the KIR-CAR platform is different
Verismo’s multi-chain KIR-CAR design is not like standard single-chain CAR T cells. It targets mesothelin and is built to tackle problems like T cell exhaustion and cytokine-driven toxicity. The company’s data point to a more controlled and possibly safer effect in animal models. These claims still need proof in human trials. For now, investors are watching for new clinical updates from Verismo and HLB's CAR-T programs. Past results in solid tumors have not moved the market as much, according to recent eDaily coverage.
The STAR-101 Phase 1 trial is testing SynKIR™-110 in patients. But the SITC 2026 data are preclinical only. No patient outcomes or clinical responses are part of this release. The field is moving fast. Other CAR T cell trials for solid tumors have drawn attention, as seen in recent coverage.
What’s planned for SITC 2026
Verismo’s poster will be in the Poster Hall at the Phoenix Convention Center. Presentation times are Friday, November 6, 2026, from 10 AM to 2 PM and again from 5 to 7 PM Mountain Time. The abstract is number 253. Its title: “Mesothelin-targeted Multi-Chain Killer Immunoglobulin Receptor (KIR)-based CAR T Reduces Exhaustion, Cytokine Release, and Enhances Safety Profile in vivo vs CD28 or 41BB single-chain CAR T.” Registration for the SITC 41st Annual Meeting 2026 is open for those interested in new immunotherapy research.
Verismo Therapeutics has reported ongoing financial losses, with a recent industry review noting revenue of 100 million won for the first half of the year and a net loss of 20.3 billion won, reflecting the high investment phase typical for early-stage biotech companies.
Verismo is making a clear move by sharing these preclinical results. The company wants its KIR-CAR platform to stand out in cell therapy. The data are early and come only from animal models. Still, the focus on less exhaustion and lower cytokine release tackles real problems in CAR T development. The real proof will come as SynKIR™-110 moves through clinical trials. For now, Verismo is betting its multi-chain KIR-CAR approach can claim a spot in the crowded immunotherapy race.
